Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours
- Author
- RAJAN, N1 ; ELLIOTT, R2 ; CLEWES, O1 ; MACKAY, A2 ; REIS-FILHO, J. S2 ; BURN, J1 ; LANGTRY, J3 ; SIEBER-BLUM, M1 ; LORD, C. J2 ; ASHWORTH, A2
[1] Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
[2] The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
[3] Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom - Source
Oncogene (Basingstoke). 2011, Vol 30, Num 41, pp 4243-4260, 18 p ; ref : 2 p
- ISSN
- 0950-9232
- Scientific domain
- Cell biology, histology; Medical oncology; Genetics
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- CYLD TRK comparative genomic hybridization cylindroma microarray tropomyosin receptor kinase
- Keyword (fr)
- Carcinogenèse Cylindrome Hybridation génomique comparative Microréseau Récepteur biologique Tropomyosin kinase Tumeur Enzyme Transferases
- Keyword (en)
- Carcinogenesis Cylindroma Comparative genomic hybridization Microarray Biological receptor Tropomyosin kinase Tumor Enzyme Transferases
- Keyword (es)
- Carcinogénesis Cilindroma Hibridación genómica comparativa Microarreglo Receptor biológico Tropomyosin kinase Tumor Enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A04 Molecular and cellular biology / 002A04F Cell structures and functions / 002A04F03 Cell receptors / 002A04F03F Miscellaneous
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A04 Molecular and cellular biology / 002A04H Cell physiology / 002A04H04 Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes
- Discipline
- Molecular and cell biology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24623858
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/onc.2011.133 
https://dx.doi.org/10.1038/onc.2011.133
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"41\";s:8:\"\u0000*\u0000spage\";s:4:\"4243\";s:8:\"\u0000*\u0000epage\";s:4:\"4260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RAJAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"ELLIOTT, R\";i:1;s:9:\"CLEWES, O\";i:2;s:9:\"MACKAY, A\";i:3;s:16:\"REIS-FILHO, J. S\";i:4;s:7:\"BURN, J\";i:5;s:10:\"LANGTRY, J\";i:6;s:14:\"SIEBER-BLUM, M\";i:7;s:10:\"LORD, C. J\";i:8;s:11:\"ASHWORTH, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"41\";s:8:\"\u0000*\u0000spage\";s:4:\"4243\";s:8:\"\u0000*\u0000epage\";s:4:\"4260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RAJAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"ELLIOTT, R\";i:1;s:9:\"CLEWES, O\";i:2;s:9:\"MACKAY, A\";i:3;s:16:\"REIS-FILHO, J. S\";i:4;s:7:\"BURN, J\";i:5;s:10:\"LANGTRY, J\";i:6;s:14:\"SIEBER-BLUM, M\";i:7;s:10:\"LORD, C. J\";i:8;s:11:\"ASHWORTH, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"41\";s:8:\"\u0000*\u0000spage\";s:4:\"4243\";s:8:\"\u0000*\u0000epage\";s:4:\"4260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RAJAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"ELLIOTT, R\";i:1;s:9:\"CLEWES, O\";i:2;s:9:\"MACKAY, A\";i:3;s:16:\"REIS-FILHO, J. S\";i:4;s:7:\"BURN, J\";i:5;s:10:\"LANGTRY, J\";i:6;s:14:\"SIEBER-BLUM, M\";i:7;s:10:\"LORD, C. J\";i:8;s:11:\"ASHWORTH, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"41\";s:8:\"\u0000*\u0000spage\";s:4:\"4243\";s:8:\"\u0000*\u0000epage\";s:4:\"4260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RAJAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"ELLIOTT, R\";i:1;s:9:\"CLEWES, O\";i:2;s:9:\"MACKAY, A\";i:3;s:16:\"REIS-FILHO, J. S\";i:4;s:7:\"BURN, J\";i:5;s:10:\"LANGTRY, J\";i:6;s:14:\"SIEBER-BLUM, M\";i:7;s:10:\"LORD, C. J\";i:8;s:11:\"ASHWORTH, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2011.133\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"41\";s:8:\"\u0000*\u0000spage\";s:4:\"4243\";s:8:\"\u0000*\u0000epage\";s:4:\"4260\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RAJAN\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:10:\"ELLIOTT, R\";i:1;s:9:\"CLEWES, O\";i:2;s:9:\"MACKAY, A\";i:3;s:16:\"REIS-FILHO, J. S\";i:4;s:7:\"BURN, J\";i:5;s:10:\"LANGTRY, J\";i:6;s:14:\"SIEBER-BLUM, M\";i:7;s:10:\"LORD, C. J\";i:8;s:11:\"ASHWORTH, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
